The Children's Investment Fund (TCI)
The Children's Investment Fund (TCI) is an activist London based hedge fund founded by Chris Hohn in 2003. TCI derives its name from a foundation called The Children's Investment Fund Foundation (CIFF) run by Hohn's wife, Jamie Cooper-Hohn. A portion of TCI's profits go to The Children's Investment Fund Foundation making it one of Great Britain's largest charities.
TCI aims to bring a long-term and owner-oriented investing philosophy to the public markets. The firm only takes capital from investors that will commit for multi-year periods. TCI uses a fundamental approach to identify attractive investments and seeks to maintain a constructive, open dialogue with management teams and boards of the companies in which it invests. However, TCI will take active roles if it feels the board and management are not acting in the best interests of the shareholders.
After management at the publicly traded German stock exchange, the Deutsche Borse, ignored the shareholders requests to vote on the proposed acquisition of the London Stock Exchange (LSE) was ignored, TCI successfully fought for board and management change. Afterwards, Deutsche Borse increased in value by 400%.
View Older Stories
-
RBC Capital Downgrades Intra-Cellular Therapies (ITCI) to Sector Perform
-
Piper Sandler Downgrades Intra-Cellular Therapies (ITCI) to Neutral
-
RBC Capital Explores Biotech Implications Following Cavazzoni's Departure from the FDA
-
Morgan Stanley Downgrades Intra-Cellular Therapies (ITCI) to Equalweight
-
Johnson & Johnson (JNJ) Acquires Intra-Cellular Therapies (ITCI) for $132/sh Cash or $14.6B
-
J&J (JNJ) in Talks to Buy Intra-Cellular (ITCI) - Bloomberg
-
Intra-Cellular Therapies (ITCI) PT Raised to $140 at Mizuho
-
Intra-Cellular Therapies (ITCI) PT Raised to $118 at BofA Securities
-
Piper Sandler Highlights NBIX, ITCI, ALKS, AXSM as High Conviction Ideas in Biotechnology
-
Biopharma 2025 Preview: 'Piper Sandler Sees Lots of Upside Opportunity'
-
RBC Capital's Game Changers: 'Disruptive Forces in Biotech'
-
Mizuho Reiterates Outperform Rating on Intra-Cellular Therapies (ITCI)
-
Intra-Cellular Therapies (ITCI) Reports Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA
-
Intra-Cellular Therapies (ITCI) PT Raised to $79 at Goldman Sachs
-
Intra-Cellular Therapies (ITCI) Misses Q3 EPS by 7c ; Offers Guidance
-
Piper Sandler Upgrades Intra-Cellular Therapies (ITCI) to Overweight
-
Intra-Cellular Therapies (ITCI) PT Raised to $81 at JPMorgan
-
Intra-Cellular Therapies (ITCI) PT Lowered to $106 at RBC Capital
-
Intra-Cellular Therapies (ITCI) Appoints Sanjeev Narula as CFO
-
Intra-Cellular Therapies (ITCI) Tops Q2 EPS by 3c ; Offers Guidance
-
RBC's biotech survey shows investors more bearish vs. last time
-
Intra-Cellular Therapies (ITCI) PT Raised to $79 at JPMorgan
-
Intra-Cellular Therapies (ITCI) PT Raised to $100 at Needham
-
UBS Downgrades Intra-Cellular Therapies (ITCI) to Neutral (earlier)
-
RBC Capital Reiterates Outperform Rating on Intra-Cellular Therapies (ITCI), 'We remain buyers'
-
Intra-Cellular Therapies (ITCI) PT Raised to $100 at Mizuho, 'Top Pick'
-
Intra-Cellular Therapies (ITCI) PT Raised to $103 at RBC Capital
-
Intra-Cellular Therapies (ITCI) Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
-
RBC Capital Reiterates Outperform Rating on Intra-Cellular Therapies (ITCI)
-
PayPal and Oracle are new top picks at Mizuho
-
RBC Capital Reiterates Outperform Rating on Intra-Cellular Therapies (ITCI)
-
Intra-Cellular Therapies (ITCI) PT Lowered to $96 at RBC Capital
-
JPMorgan on Intra-Cellular Therapies (ITCI): 'We continue to like ITCI stock'
-
Jefferies Positive on Intra-Cellular Therapies (ITCI): 'We like the setup ahead of the second MDD readout in late-Q2'
-
Intra-Cellular Therapies (ITCI) Tops Q1 EPS by 16c ; Offers Guidance
-
Intra-Cellular Therapies (ITCI) PT Raised to $107 at Canaccord Genuity
-
Intra-Cellular Therapies (ITCI) PT Raised to $96 at Mizuho
-
Intra-Cellular Therapies (ITCI) Prices Public Offering of Common Stock
-
Intra-Cellular Therapies (ITCI) PT Raised to $103 at Baird
-
Intra-Cellular Therapies (ITCI) PT Raised to $91 at BofA Securities
-
Intra-Cellular Therapies (ITCI) Announces Proposed $500M Share Offering
-
Intra-Cellular Therapies (ITCI) Files Mixed Shelf
-
Midday movers: Morgan Stanley, UnitedHealth rise; Tesla falls
-
Mizuho positive on Intra-Cellular Therapies (ITCI), 'potential for the stock to move even higher'
-
Intra-Cellular Therapies (ITCI) to Resume Trading at 7:30 a.m.
-
Intra-Cellular Therapies (ITCI) Reports Positive Phase 3 Topline Results from Study 501
-
Intra-Cellular Therapies (ITCI) Halted, News Pending
-
These 8 stocks are the latest additions to Mizuho's Top Picks list
-
Intra-Cellular Therapies (ITCI) Announces Leadership Changes
-
Intra-Cellular Therapies (ITCI) Tops Q4 EPS by 15c, provides guidance

